CAMP
Camp4 Therapeutics Corp
NASDAQ · Healthcare · Biotechnology · US
$3.14
−0.95%Year over year
Reported trailing growth
- Revenue
- +40.2%
- EBITDA
- -39.7%
- EBIT
- +2.4%
- EPS
- +15.2%
- Free cash flow
- +37.8%
- Operating cash flow
- +37.3%
Forward estimates
Based on analyst estimates
- Revenue
- +96.4%
- EBITDA
- +49.9%
- EPS
- +69.9%
Three-year CAGR
- Revenue
- -77.2%
- EBITDA
- +1.9%
- EBIT
- +1.9%
- Net income
- -55.2%
- EPS
- +0.4%
- Free cash flow
- +35.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026